Nanofibre platform shows potential for inhibiting brain tumour growth
Scientists have created a nanofibre-based sheet to control and direct the migration of cells, possibly leading to brain tumour therapies.
List view / Grid view
Scientists have created a nanofibre-based sheet to control and direct the migration of cells, possibly leading to brain tumour therapies.
Washington University will receive $7.5 million from the NIH to study senescent cells for treatments against age-related diseases.
Scientists have identified potential cancer drugs to treat pulmonary hypertension using experimental and computational approaches.
In a new study, a calorie-restricted diet significantly reduced tumour growth in mouse models, suggesting new possibilities for cancer therapies.
The statistical method known as maximum entropy could improve cryogenic electron microscopy (cryo-EM) for more effective drug treatments.
The antimicrobial hygromycin A was shown to clear Lyme disease in mice, representing a promising therapeutic against the disease.
Scientists have developed a novel technique for the targeted clearance of senescent cells to improve treatments for ageing and other conditions.
Mammalian target of rapamycin complex 2 (mTORC2) was found to prevent brain damage in mice infected with herpes simplex virus 1 (HSV-1).
Medicenna's IL-2 super-agonist, MDNA11, successfully induced antitumour cells in animal models, a pre-clinical study has revealed.
New dendritic hydrogels were tested against several infectious bacteria and could be used as an an antibiotic-free treatment in the future.
Researchers have shown that a new microneedle vaccine patch was 10 times stronger at generating an immune response in animals than a subcutaneous injection.
A new antiviral has shown promise against the dengue virus in mice and has the potential to be used as a preventative measure.
The metagenomic method, termed SMAGLinker, could improve the accuracy and resolution of microbial characterisation to improve medicine design.
Researchers identified three microRNAs whose levels were associated with mental performance in cells, mice and humans.
Mission Therapeutics was granted $500,000 from the The Michael J Fox Foundation for Parkinson’s Research for DUB inhibitor testing.